Document is current
Any future updates will be listed below
-
Authors
Dugan, Michelle M.
Aflatooni, Shaliz
Mullinax, John E.
Zager, Jonathan S. https://orcid.org/0000-0002-6886-4468
- License Information
-
More Information
Article History
Received: 4 September 2024
Accepted: 10 September 2024
First Online: 21 September 2024
Disclosure
: Moffitt Cancer Center has licensed intellectual property (IP) related to the proliferation and expansion of tumor-infiltrating lymphocytes (TILs) to Iovance Biotherapeutics. John E. Mullinax is an inventor of such intellectual property and has participated in sponsored research agreements with Iovance Biotherapeutics, Intellia Therapeutics, and SQZ Biotech. Dr. Mullinax has received research support from the following entities: NIH-NCI (K08CA252642), Ocala Royal Dames, and V Foundation. He has received ad hoc consulting fees from Merit Medical, Lyell Immunopharma, and Iovance Biotherapeutics. Jonathan S. Zager is the US patent holder of high flow isolated limb infusion, he receives honoraria/personal consulting fees from Merck, Merit Medical, Menarini Silicon Biosystems, Replimune, Philogen, GLG, Guidepoint and is on the Delcath Medical Advisory Board. The remaining authors have no conflicts of interest.
